Enhanced antitumoral activity of the academic CAR-T ARI0002h against normal and low BCMA-expressing myeloma cells after incorporating a transmembrane CD28 domain - PubMed
12 hours ago
- #CAR-T therapy
- #BCMA
- #Multiple Myeloma
- The academic CAR-T ARI0002h was enhanced by incorporating a transmembrane CD28 domain (CD28-TMD) to improve its efficacy against multiple myeloma (MM) cells, including those with low BCMA expression.
- The modified CAR-T, ARI2h-TM28, demonstrated superior in vivo tumor control and survival in relapse models with antigen downregulation, compared to the original ARI0002h.
- ARI2h-TM28 showed an optimized metabolic profile, reduced exhaustion, and increased persistence, contributing to improved efficacy in preclinical models.
- The study suggests that the CD28-TMD modification enhances long-term disease management by increasing potency against MM cells with both normal and reduced BCMA expression.
- Conflict of interest disclosures include various honoraria, travel grants, and research funding from pharmaceutical companies related to the authors.